ARMATA PHARMACEUTICALS, INC. Research and Development Expense
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Research and Development Expense of $9.82 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-03-19
- ARMATA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2019-03-31 was $1.49M, a 2.05% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2018-12-31 was $4.86M, a 345.41% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2018-09-30 was $361.00K.
- ARMATA PHARMACEUTICALS, INC. research and development expense for the quarter ending 2018-06-30 was $1.69M, a 49.73% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. research and development expense for fiscal 2019 was $9.82M, a 17.34% increase from fiscal 2018.
- ARMATA PHARMACEUTICALS, INC. research and development expense for fiscal 2018 was $8.37M, a 190.59% increase from fiscal 2017.
- ARMATA PHARMACEUTICALS, INC. research and development expense for fiscal 2017 was $2.88M, a 49.26% decline from fiscal 2016.
- ARMATA PHARMACEUTICALS, INC. research and development expense for fiscal 2016 was $5.68M, a 42.23% increase from fiscal 2015.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $9.82M 10-K · filed 2020-03-19 | |||||||
| 2019-03-31 | $1.49M 10-Q · filed 2019-05-06 | $6.35M derived: sum of 2 quarters · filed 2020-03-19 | $6.71M derived: sum of 3 quarters · filed 2020-03-19 | $8.40M derived: sum of 4 quarters · filed 2020-03-19 | ||||
| 2018-12-31 | $4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $5.22M derived: sum of 2 quarters · filed 2020-03-19 | $6.91M derived: sum of 3 quarters · filed 2020-03-19 | $8.37M 10-K · filed 2020-03-19 | $4.89M 10-K · filed 2019-03-25 | |||
| 2018-09-30 | $361.00K 10-Q · filed 2018-11-08 | $2.05M derived: sum of 2 quarters · filed 2018-11-08 | $3.52M 10-Q · filed 2018-11-08 | $4.61M derived: sum of 4 quarters · filed 2019-05-06 | ||||
| 2018-06-30 | $1.69M 10-Q · filed 2018-08-09 | $3.16M 10-Q · filed 2018-08-09 | $4.25M derived: sum of 3 quarters · filed 2019-05-06 | $3.42M derived: sum of 4 quarters · filed 2019-05-06 | ||||
| 2018-03-31 | $1.46M 10-Q · filed 2019-05-06 | $2.55M derived: sum of 2 quarters · filed 2019-05-06 | $1.73M derived: sum of 3 quarters · filed 2019-05-06 | $2.85M derived: sum of 4 quarters · filed 2019-05-06 | ||||
| 2017-12-31 | $1.09M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | $261.00K derived: sum of 2 quarters · filed 2019-03-25 | $1.39M derived: sum of 3 quarters · filed 2019-03-25 | $2.88M 10-K · filed 2019-03-25 | ||||
| 2017-09-30 | -$829.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $301.00K derived: sum of 2 quarters · filed 2018-11-08 | $1.79M 10-Q · filed 2018-11-08 | $2.59M derived: sum of 4 quarters · filed 2018-11-08 | ||||
| 2017-06-30 | $1.13M 10-Q · filed 2018-08-09 | $2.62M 10-Q · filed 2018-08-09 | $3.42M derived: sum of 3 quarters · filed 2018-08-09 | $5.08M derived: sum of 4 quarters · filed 2018-08-09 | ||||
| 2017-03-31 | $1.49M 10-Q · filed 2018-05-15 | $2.29M derived: sum of 2 quarters · filed 2018-05-15 | $3.95M derived: sum of 3 quarters · filed 2018-05-15 | $5.19M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2016-12-31 | $802.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $2.46M derived: sum of 2 quarters · filed 2018-03-14 | $3.70M derived: sum of 3 quarters · filed 2018-03-14 | $5.68M 10-K · filed 2018-03-14 | ||||
| 2016-09-30 | $1.66M 10-Q · filed 2016-11-10 | $2.90M derived: sum of 2 quarters · filed 2017-08-14 | $4.88M 10-Q · filed 2016-11-10 | $6.09M derived: sum of 4 quarters · filed 2017-08-14 | ||||
| 2016-06-30 | $1.24M 10-Q · filed 2017-08-14 | $3.22M 10-Q · filed 2017-08-14 | $4.44M derived: sum of 3 quarters · filed 2017-08-14 | $5.16M derived: sum of 4 quarters · filed 2017-08-14 | ||||
| 2016-03-31 | $1.98M 10-Q · filed 2017-05-15 | $3.19M derived: sum of 2 quarters · filed 2017-05-15 | $3.92M derived: sum of 3 quarters · filed 2017-05-15 | $5.00M derived: sum of 4 quarters · filed 2017-05-15 | ||||
| 2015-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | $1.94M derived: sum of 2 quarters · filed 2017-03-27 | $3.02M derived: sum of 3 quarters · filed 2017-03-27 | $3.99M 10-K · filed 2017-03-27 | ||||
| 2015-09-30 | $728.00K 10-Q · filed 2016-11-10 | $1.80M derived: sum of 2 quarters · filed 2016-11-10 | $2.78M 10-Q · filed 2016-11-10 | $3.89M derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $1.08M 10-Q · filed 2016-08-15 | $2.05M 10-Q · filed 2016-08-15 | $3.16M derived: sum of 3 quarters · filed 2016-08-15 | $4.96M derived: sum of 4 quarters · filed 2016-08-15 | ||||
| 2015-03-31 | $972.00K 10-Q · filed 2016-05-12 | $2.08M derived: sum of 2 quarters · filed 2016-05-12 | $3.88M derived: sum of 3 quarters · filed 2016-05-12 | $5.77M derived: sum of 4 quarters · filed 2016-05-12 | ||||
| 2014-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $2.91M derived: sum of 2 quarters · filed 2016-03-30 | $4.79M derived: sum of 3 quarters · filed 2016-03-30 | $5.80M 10-K · filed 2016-03-30 | ||||
| 2014-09-30 | $1.79M 10-Q · filed 2015-11-16 | $1.80M 10-Q · filed 2014-11-14 | $3.68M derived: sum of 2 quarters · filed 2015-11-16 | $4.69M 10-Q · filed 2015-11-16 | $4.69M 10-Q · filed 2014-11-14 | $5.80M derived: sum of 4 quarters · filed 2015-11-16 | ||
| 2014-06-30 | $1.89M 10-Q · filed 2015-08-13 | $1.88M 10-Q · filed 2014-09-12 | $2.90M 10-Q · filed 2015-08-13 | $2.88M 10-Q · filed 2014-09-12 | $4.01M derived: sum of 3 quarters · filed 2015-08-13 | $5.13M derived: sum of 4 quarters · filed 2015-08-13 | ||
| 2014-03-31 | $1.01M 10-Q · filed 2015-05-15 | $1.01M 10-Q · filed 2014-05-20 | $2.12M derived: sum of 2 quarters · filed 2015-05-15 | $3.24M derived: sum of 3 quarters · filed 2015-05-15 | $6.84M derived: sum of 4 quarters · filed 2015-05-15 | |||
| 2013-12-31 | $1.11M derived: 10-Q/A 12 month − 10-Q/A 9 month · filed 2015-04-15 | $2.23M derived: sum of 2 quarters · filed 2015-04-15 | $5.83M derived: sum of 3 quarters · filed 2015-04-15 | $6.47M 10-Q/A · filed 2015-04-15 | $6.50M 10-Q · filed 2014-05-20 | |||
| 2013-09-30 | $1.12M 10-Q/A · filed 2015-04-15 | $1.11M 10-Q · filed 2014-11-14 | $4.72M derived: sum of 2 quarters · filed 2015-04-15 | $5.36M 10-Q/A · filed 2015-04-15 | $5.38M 10-Q · filed 2014-11-14 | |||
| 2013-06-30 | $3.60M 10-Q/A · filed 2015-04-15 | $3.72M 10-Q · filed 2014-09-12 | $4.24M 10-Q/A · filed 2015-04-15 | $4.27M 10-Q · filed 2014-09-12 | ||||
| 2013-03-31 | $641.00K 10-Q/A · filed 2015-04-15 | $551.00K 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |